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ADVOCATES of personalised 
medicine claim that healthcare 
isn’t individualised enough.
Backed up by the glamour of 
new biotechnologies such as 
direct-to-consumer genetic 
testing, personalised medicine – 
what I call “Me Medicine” – 
appears to its advocates as the 
inevitable and desirable way to go. 
Barack Obama, when still a US 
senator, declared that “in no area 
of research is the promise greater 
than in personalised medicine”.
This trend towards Me Medicine 
is led by the US, but it is growing 
across the developed world.
In contrast, “We Medicine” – 
public-health programmes such 
as flu shots or childhood 
vaccination – is increasingly 
distrusted and vulnerable to 
austerity cuts. Yet historically  
this approach has produced the 
biggest increase in lifespan. Even 
today, countries with more social 
provision of healthcare and less 
individualistic attitudes have 
better health outcomes across 
all social classes.
Contrary to the claims of its 
proponents, the personalised 
approach hasn’t yet delivered a 
paradigm shift in medicine. A 2012 
Harris poll of 2760 US patients 
and physicians found that doctors 
had recommended personal 
genetic tests for only 4 per cent  
of patients. The Center for Health 
Reform & Modernization, run  
by US healthcare company 
UnitedHealth, put the figure  
at just 2 per cent.
But money is still pouring into 
Me Medicine. In July, the UK 
government announced that it 
would offer private companies a 
subsidy from a £300 million fund 
to encourage investment in its 
personalised medicine initiative, 
Genomics England. Last year the 
US administration increased the 
National Institutes of Health 
budget for personalised medicine, 
while cutting the budget for the 
Centers for Disease Control and 
Prevention’s Office of Public 
Health Genomics by 90 per cent.
Of course it would be nice if we 
could afford both, but in reality 
there’s a growing risk that “me” 
will edge out “we”. If it does, it 
won’t be because the science is 
better or the outcomes more 
beneficial. In some instances of 
Me Medicine, clinical outcomes 
are worse than the We equivalent. 
For example, according to the 
UK’s Royal College of Obstetricians 
and Gynaecologists, private 
umbilical cord blood banks, which 
ostensibly provide a personal 
“spare parts kit” for the baby, 
produce poorer outcomes than 
public cord blood banking.
It is true that in some areas of 
Me Medicine, such as genetically 
individualised drug regimes for 
cancer care (technically known  
as pharmacogenetics), there  
has been genuine progress. For 
example, vemurafenib, a drug 
for aggressive melanoma, was 
reported in a 2012 New England 
Journal of Medicine article to 
extend the lifespan of 1 in 4 
patients by seven months if they 
carry a specific genetic mutation 
in their cancer.
But only about half of those 
with the “right” type of tumour 
responded, and the mutation  
in question only occurs in about 
half of such melanomas. What is 
more, pharmaceutical firms will 
probably charge more for such 
drugs than for mass-market ones. 
They will be expensive, may 
benefit only a subset of the 
population and could leave cash-
strapped state healthcare systems 
facing difficult decisions about 
where to allocate resources.
A month after the melanoma 
study, much less encouraging 
results for pharmacogenetics 
were reported in another NEJM 
article. A genome-wide analysis  
of biopsies on four people with 
kidney cancer showed that 
separate samples from the  
same tumour can have different 
mutations, so a drug that targets 
one may leave other parts of the 
tumour untreated.
Given that the scientific 
evidence alone doesn’t explain 
all the interest in personalised 
medicine, what does? Many retail 
genetics companies have “me” in 
their name – notably 23andMe, 
DeCODEme and Knome – so does 
it boil down to narcissism? I doubt 
it. There’s nothing narcissistic 
about pharmacogenetics.
Another possible explanation  
is the favourable connotations  
of “personal” and “choice”. “We” 
measures such as childhood 
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vaccination are routinely attacked 
as an invasion of parental choice, 
while accounts by people who 
have paid to have genetic profiles 
drawn up often include themes  
of individual self-discovery.
A third explanation is 
commercial: that in personalised 
medicine, pharmaceutical 
companies see a way to rescue 
themselves from the demise of 
profitable patents on mass-market 
drugs, so they promote the shift 
from We to Me.
As Mark Levin, former CEO  
of Millennium Pharmaceuticals, 
put it in 2012: “Business 
incentives must be put in place 
to encourage private investment 
and further develop the pipeline 
of new personalised medicine 
products.”
The landscape has clearly 
changed. Twenty years ago, who 
could have predicted that people 
would pay to have a spit sample 
genetically tested or to bank their 
child’s umbilical cord blood? 
As well as unpicking and 
unpacking the science, we need  
to consider the social and 
economic context behind Me 
Medicine. How can we balance the 
role of the individual and the 
communal in healthcare? And 
how did we move from the 
original vision of genetic 
biomedicine as a communitarian 
endeavour – the Human Genome 
Project was ostensibly for the 
benefit of all humankind – to the 
personalised medicine paradigm?
These are big questions that 
need to be asked. If we do embrace 
personalised medicine, it should 
only be after a thorough review of 
the evidence and careful analysis 
of the social landscape in which 
we’re making that choice.  n
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Your new company, Sent Into Space, sells 
do-it-yourself kits to send objects up into  
the stratosphere. How did you get started? 
Alex: Weather balloons have been around for a 
while as a way to collect data. We thought it would 
be fun to put a camera on one and see where it 
went. For the first flight a couple of years ago, we 
just botched something together: a camera, some 
foam we found in a bin and a GPS tracker normally 
used to track pets. It worked – but only just. We 
posted a video online, and some Canadian guys 
saw it and sent a Lego man up. Soon people were 
asking how they could have a go themselves. 
How did you go from there to a business? 
Chris: We didn’t really anticipate the attention  
it would get. We gave a lot of tips to people,  
and were getting so many requests for help  
that we thought we should make a kit for the  
non-specialist. We designed and manufactured 
components to make it as reliable and simple as 
possible. We hope to sell the finished product in 
shops and through our website, so that anyone 
can do this themselves. 
Will you still advise people? 
Alex: That’s the other side of it. If people have a 
project in mind, we see what we can do to make it 
happen. We did a launch for a music festival and a 
publicity campaign for the University of Sheffield. 
We have also worked with an astrobiologist who 
wanted to take samples from the stratosphere. 
And we do projects with schools, which is a great 
way to get kids enthusiastic about science in a 
hands-on way. They’re putting stuff into space! 
Does the kit contain everything you need? 
Chris: You get the balloon, parachute, container 
for the payload, tracking devices and a computer 
system that we call the black box. It records the 
data – including GPS, altitude, pressure, humidity, 
temperature and acceleration. Schools really enjoy 
having all of that information after the flight.  
You just have to get the helium – we tell you the 
nearest provider – and apply for clearance from 
the Civil Aviation Authority a month in advance. 
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Can you describe a typical flight? How high 
and far can the balloons go? 
Alex: They can go up to about 38 kilometres. That 
is technically near space rather than space, but 
you can see the blackness of space during the day. 
It normally takes a couple of hours for the balloon 
to reach that height. As the pressure drops with 
altitude, the balloon expands until it finally bursts; 
they start 2 metres across and get to about 
10 metres. When the balloon bursts, a parachute 
opens and it takes about an hour to come down. 
On our website, we link to software that helps you 
make quite accurate predictions about where it 
will land – anywhere up to about 100 miles away. 
What do people who buy the kits usually  
do with them? 
Chris: Some people want to use it as a tool for 
taking pictures from high altitudes. Others want  
to send up their personal belongings just to be 
able to say they have been into space. But every 
project we do is exciting. We still get giddy when 
tracking the thing coming down.
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